Display options
Cite
Fox JM. Coffein plus Analgetika-eine sinnvolle Kombination. [Caffeine plus analgesics-a significant combination.]. Schmerz. 1988;2(4):183-97doi: 10.1007/BF02527916.
Fox, J. M. (1988). Coffein plus Analgetika-eine sinnvolle Kombination. [Caffeine plus analgesics-a significant combination.]. Schmerz (Berlin, Germany), 2(4), 183-97. https://doi.org/10.1007/BF02527916
Fox, J M. "Coffein plus Analgetika-eine sinnvolle Kombination." [Caffeine plus analgesics-a significant combination.]. Schmerz (Berlin, Germany) vol. 2,4 (1988): 183-97. doi: https://doi.org/10.1007/BF02527916
Fox JM. Coffein plus Analgetika-eine sinnvolle Kombination. [Caffeine plus analgesics-a significant combination.]. Schmerz. 1988 Dec;2(4):183-97. doi: 10.1007/BF02527916. German. PMID: 18415280.
Copy Download .nbib Format: NLM
Share it on

Schmerz. 1988 Dec;2(4):183-97. doi: 10.1007/BF02527916.

[Caffeine plus analgesics-a significant combination.].

Schmerz (Berlin, Germany)

[Article in German]
J M Fox

Affiliations

  1. Fachbereich 3 (Theoretische Medizin) der Universität des Saarlandes, Köln, Deutschland.

PMID: 18415280 DOI: 10.1007/BF02527916

Abstract

Since the ban of phenacetin and barbiturates in analgesics, caffeine as a constituent of analgesics has recently more often been blamed for promoting the abuse of analgesics. The available relevant literature was reviewed to perform a benefit/risk analysis. The results were as follows. The capability of caffeine to potentiate analgesia was demonstrated in controlled clinical trials involving approximately 12000 patients. This effect does not mean that there is a stronger analgesic effect, but that the addition of caffeine allows to reduce the dose of analgesics significantly, while maintaining the same analgesic efficacy. A minimum single dose of 50 mg caffeine is required to achieve this potentiation. Furthermore, it was demonstrated in controlled clinical trials in about 2000 patients that the maximum analgesic effect is achieved after 30-45 min with caffeine-containing analgesics, but only after 60-90 min with monotherapy. This must be regarded as a great advantage in terms of cumulative toxicity, because additional or higher doses due to insufficienttimeliness of efficacy are thus avoided. Thus, the analgesic benefit of caffeine as a constituant of analgesic drugs can no longer be denied, even though some studies leave room for criticism. (It should be added that this beneficial effect was investigated only for acute treatment with acetylsalicylic acid plus caffeine or with paracetamol plus caffeine). Toxicity studies with combination drugs indicate that there are no risks beyond the known risks of the individual components. On the contrary, the studies suggest that there is a tendency towards underadditivity; with an equal analgesic efficacy, therefore, the toxicological risk of an analgesic plus caffeine tends to be lower than with the respective analgesic alone. With respect to the frequently postulated promotion of analgesic abuse by caffeine, the results of this review are best summarized by citing the statement of the Federal Drug Review Committee "Neurology/Psychiatry" at the Bundesgesundheitsamt (BGA): "There is no evidence showing that a possible potential for dependence in the case of analgesics, such as acetylsalicylic acid or paracetamol, is increased by caffeine. Even though this could be assumed in theory, based on the available data there is no proof of an additional abuse potential for caffeine in combination with analgesics" [11]. The question of whether combination analgesics containing caffeine ought to be sold only on prescription might better be answered in the negative; in Germany, the percentage of self-medication (i.e., without consulting the doctor) in the consumption of prescription analgesics reaches up to 40% (1). Furthermore one could even argue that by introducing prescription schedule for analgesics containing caffeine a higher consumption of analgesic substance might be induced (to achieve an analgesic efficacy equal to that of combination drugs). This however might cause a higher and unpredictable risk (e.g., gastrointestinal bleeding) with proper use in exchange for of a reduction in the predictable risk with misuse or abuse. This would raise major ethical and legal issues. Minimizing one special risk does not automatically reduce the overall risk.

References

  1. J Pharmacol Exp Ther. 1986 Nov;239(2):416-25 - PubMed
  2. J Pharm Pharmacol. 1979 Dec;31(12):840-8 - PubMed
  3. Schweiz Med Wochenschr. 1985 Jun 8;115(23):790-5 - PubMed
  4. Fortschr Med. 1982 Jun 17;100(23):1111-5 - PubMed
  5. Am J Med. 1983 Nov 14;75(5A):139-40 - PubMed
  6. J Exp Anal Behav. 1986 Mar;45(2):133-48 - PubMed
  7. J Int Med Res. 1984;12(6):338-45 - PubMed
  8. JAMA. 1985 Feb 8;253(6):779-80 - PubMed
  9. Clin Pharmacol Ther. 1983 Apr;33(4):498-509 - PubMed
  10. Drugs. 1982 Jan-Feb;23(1-2):75-149 - PubMed
  11. Int J Cancer. 1981;27(4):521-9 - PubMed
  12. Pharm Weekbl Sci. 1986 Aug 22;8(4):239-43 - PubMed
  13. Schweiz Med Wochenschr. 1961 Dec 16;91:1529-31 - PubMed
  14. Arzneimittelforschung. 1976;26(11):2059-61 - PubMed
  15. Med Monatsschr Pharm. 1984 Dec;7(12):354-7 - PubMed
  16. Toxicology. 1985 Feb;34(2):95-101 - PubMed
  17. Dtsch Med Wochenschr. 1986 Sep 12;111(37):1414-5 - PubMed
  18. Ergeb Inn Med Kinderheilkd. 1974;35:67-175 - PubMed
  19. Br J Addict. 1983 Sep;78(3):251-8 - PubMed
  20. MMW Munch Med Wochenschr. 1975 Mar 14;117(11):457-62 - PubMed
  21. JAMA. 1984 Apr 6;251(13):1732-3 - PubMed
  22. Indian J Med Res. 1978 Nov;68:844-8 - PubMed
  23. MMW Munch Med Wochenschr. 1978 Jun 2;120(22):765-6 - PubMed
  24. Can Med Assoc J. 1985 Aug 15;133(4):294-6 - PubMed
  25. N Engl J Med. 1983 Feb 17;308(7):357-62 - PubMed
  26. Psychopharmacology (Berl). 1988;94(4):437-51 - PubMed
  27. Eur J Drug Metab Pharmacokinet. 1986 Jan-Mar;11(1):71-6 - PubMed
  28. JAMA. 1984 Apr 6;251(13):1711-8 - PubMed
  29. Arch Immunol Ther Exp (Warsz). 1977;25(2):175-9 - PubMed
  30. Arch Intern Med. 1981 Feb 23;141(3 Spec No):293-300 - PubMed
  31. Am J Med. 1983 Nov 14;75(5A):70-81 - PubMed
  32. Am J Med. 1984 Mar;76(3):345-8 - PubMed
  33. Dtsch Med Wochenschr. 1987 May 15;112(20):787-90 - PubMed
  34. Internist (Berl). 1986 Dec;27(12):770-7 - PubMed
  35. Kidney Int. 1978 Jan;13(1):50-7 - PubMed
  36. Klin Wochenschr. 1986 Mar 17;64(6):294-8 - PubMed
  37. N Engl J Med. 1974 May 23;290(21):1158-62 - PubMed
  38. Kidney Int. 1978 Jan;13(1):79-92 - PubMed
  39. Dtsch Med Wochenschr. 1984 Mar 9;109(10):369-73 - PubMed
  40. Dtsch Med Wochenschr. 1986 Sep 12;111(37):1416-8 - PubMed
  41. Mayo Clin Proc. 1973 May;48(5):359-67 - PubMed
  42. Acta Med Scand. 1963;174:SUPPL405:1-26 - PubMed
  43. J Pharmacol Exp Ther. 1973 Oct;187(1):185-94 - PubMed
  44. J Clin Pharmacol. 1979 Apr;19(4):242-7 - PubMed
  45. Clin Pharmacol Ther. 1978 Jul;24(1):69-75 - PubMed
  46. Ned Tijdschr Tandheelkd. 1972 Feb;79(2):69-75 - PubMed
  47. Practitioner. 1973 Nov;211(265):639-44 - PubMed
  48. Drug Chem Toxicol. 1980;3(2):135-63 - PubMed
  49. Kidney Int. 1980 Feb;17(2):250-60 - PubMed
  50. Med Klin. 1975 May 16;70(20):889-95 - PubMed
  51. Gut. 1982 Apr;23(4):340-4 - PubMed
  52. Br J Clin Pharmacol. 1980 Oct;10 Suppl 2:359S-368S - PubMed
  53. J Pharmacol Exp Ther. 1973 Aug;186(2):266-75 - PubMed
  54. Am J Med. 1984 Sep 10;77(3A):38-53 - PubMed

Publication Types